C5 and COVID-19: Ongoing RCTs that target C5 in severe COVID-19 are evaluating the monoclonal antibodies eculizumab (NCT04346797) and ravulizumab (NCT04570397 and NCT04390464), and peptide inhibitors of C5, such as zilucoplan (NCT04382755).